BET­TER WAY TO DE­LIVER MED­I­CA­TIONS

EQUUS - - Eq Medicalfront -

ma­col­ogy it eas­ier Break­throughs to could de­liver soon more in phar- make pre­cise doses of phenylbu­ta­zone (“bute”). Re­searchers at the Univer­sity of Hud­der­s­field in Eng­land have been look­ing into the po­ten­tial use of nanopar­ti­cles called meso­porous sil­i­cas as car­ri­ers of equine med­i­ca­tions. “Sil­ica has some unique phys­i­cal prop­er­ties, such as sur­face area and pore size, that al­low us to in­crease the sol­u­bil­ity of poorly wa­ter­sol­u­ble drugs such as phenylbu­ta­zone when the two are com­bined,” says Laura Waters, PhD, who noted that the study was done in col­lab­o­ra­tion with Ir­ish nano­ma­te­ri­als com­pany Glantreo Ltd. Drugs that do not read­ily dis­solve have lower bioavail­abil­ity and can be dif­fi­cult to ad­min­is­ter, a prob­lem known to any horse owner who has at­tempted to dis­solve a bute tablet in wa­ter. The British re­searchers looked at three dif­fer­ent types of meso­porous sil­i­cas and mea­sured their ef­fects on the sol­u­bil­ity of phenylbu­ta­zone. They found that all three dra­matic per­cent­age the test­ing the vent “We first drug to forms pre­dict pe­riod. mea­sured 30 dis­solved en­hance­ment min­utes dis­so­lu­tion,” “ex­hib­ited how how in fast of a the fast a sol- in it in would Waters. any drug dis­solve “This must is un­dergo in the vivo,” first be- says step fore so the it can faster work it dis­solves in the body, in our sys­tem/in vivo then the faster it will work. Also, the more that dis­solves the bet­ter. Some drugs just don’t dis­solve at all, and that can be a big prob­lem. If we can get it all to dis­solve in a short space of time then that’s best for drug de­liv­ery.” While this par­tic­u­lar study was lim­ited to bute, Waters sil­i­cas could says meso­porous help en­hance the ac­tion of many equine med­i­ca­tions. “In our work, bute was just an ex­am­ple of a drug that we know has poor sol­u­bil­ity to prove that we can po­ten­tially sal­vage a whole range of drugs that can­not be de­vel­oped fur­ther be­cause they have poor sol­u­bil­ity. The in­creased sol­u­bil­ity also means that the drug will be more likely to be effective and less needs to be ad­min­is­tered, thus re­duc­ing the like­li­hood of side ef­fects. Any drug could in the­ory be in­cor­po­rated within a sil­ica sys­tem which could im­prove their per­for­mance, re­duce the fre­quency of dos­ing or re­duce side ef­fects.” Meso­porous sil­i­cas are not cur­rently be­ing used in hu­man medicine, but Waters says that re­search is on­go­ing.

Ref­er­ence: “En­hanc­ing the dis­so­lu­tion of phenylbu­ta­zone us­ing Sy­loid-based meso­porous sil­i­cas for oral equine ap­pli­ca­tions,” Jour­nal of Phar­ma­ceu­ti­cal Anal­y­sis, June 2018

TRANS­MIS­SION ELECTRON MICROSCOPY IM­AGE OF A MESO­POROUS SIL­ICA NANOPARTICLE IN­NO­VA­TION: Re­searchers are in­ves­ti­gat­ing the po­ten­tial use of nanopar­ti­cles called meso­porous sil­i­cas as car­ri­ers of equine med­i­ca­tions.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.